<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>381</serviceExecutionTime><Drug id="10788"><DrugName>BL-22</DrugName><DrugSynonyms><Name><Value>BL-22</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NSC-691237</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RFB4(dsFv)-PE38</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca</Value></Name><Name><Value>GCR-3888</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CAT-3888</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20519">National Cancer Institute</CompanyOriginator><CompaniesSecondary><Company id="15856">Genencor International Inc</Company><Company id="16045">Enzon Pharmaceuticals Inc</Company><Company id="18008">MedImmune LLC</Company><Company id="20519">National Cancer Institute</Company><Company id="24236">Cambridge Antibody Technology Group plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10788" type="Drug"><TargetEntity id="271142" type="siDrug">RFB4(dsFv)-PE38</TargetEntity></SourceEntity><SourceEntity id="15856" type="Company"><TargetEntity id="4295900445" type="organizationId">Danisco US Inc</TargetEntity></SourceEntity><SourceEntity id="16045" type="Company"><TargetEntity id="4295906372" type="organizationId">Enzon Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="24236" type="Company"><TargetEntity id="4295894925" type="organizationId">Cambridge Antibody Technology Group Ltd</TargetEntity></SourceEntity><SourceEntity id="1728" type="ciIndication"><TargetEntity id="C91.0" type="ICD10"></TargetEntity><TargetEntity id="204" type="ICD9"></TargetEntity><TargetEntity id="513" type="ORPHANET"></TargetEntity><TargetEntity id="685" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1736" type="ciIndication"><TargetEntity id="C91.4" type="ICD10"></TargetEntity><TargetEntity id="10019053" type="MEDDRA"></TargetEntity><TargetEntity id="D007943" type="MeSH"></TargetEntity><TargetEntity id="58017" type="ORPHANET"></TargetEntity><TargetEntity id="-1237098648" type="omicsDisease"></TargetEntity><TargetEntity id="693" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"></TargetEntity><TargetEntity id="-1829786210" type="omicsDisease"></TargetEntity><TargetEntity id="699" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="53707" type="Action"><TargetEntity id="1471" type="Mechanism">Elongation Factor 2 (EF-2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00381" type="ciTarget"><TargetEntity id="16925869359333" type="siTarget">B-cell receptor CD22</TargetEntity><TargetEntity id="-1609817463" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-09718" type="ciTarget"><TargetEntity id="85855362319383" type="siTarget">Elongation factor 2</TargetEntity><TargetEntity id="9217" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1736">Hairy cell leukemia</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="316">B-cell lymphoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="53707">Elongation factor 2 inhibitor</Action><Action id="5091">B-lymphocyte cell adhesion molecule inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="339">Protein synthesis inhibitor</Action><Action id="539">Immunotoxin</Action></ActionsSecondary><Technologies><Technology id="216">Antibody conjugated</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-04-16T13:07:22.000Z</LastModificationDate><ChangeDateLast>2019-01-14T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;&lt;/ulink&gt;The &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; (NCI)  was developing BL-22, formerly CAT-3888 (GCR-3888; RFB4 (dsFV)-PE38; NSC-691237), an immunotoxin consisting of a recombinant Pseudomonas exotoxin A (PE-38),   coupled to a  monoclonal antihuman CD22 antibody (RFB4), for the potential treatment of hairy cell leukemia (HCL) [&lt;ulink linkID="987588" linkType="Reference"&gt;987588&lt;/ulink&gt;]. In February 2009, phase II trials  began [&lt;ulink linkID="987588" linkType="Reference"&gt;987588&lt;/ulink&gt;]; in April 2012, the trials were terminated as the supply of BL-22  expired and the sponsor was not interested in producing new supply [&lt;ulink linkID="987588" linkType="Reference"&gt;987588&lt;/ulink&gt;], [&lt;ulink linkID="1024708" linkType="Reference"&gt;1024708&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt; (formerly Cambridge Antibody Technology (CAT); now part of AstraZeneca), was previously developing BL-22 as CAT-3888 for the potential treatment of several cancers, in particular B-cell malignancies, under license from &lt;ulink linkID="15856" linkType="Company"&gt;Genencor&lt;/ulink&gt;.   In May 2007, phase II trials in hairy cell leukemia, phase I trials in chronic lymphocytic leukemia (CLL) and phase I trials in pediatric acute lymphoblastic leukemia were ongoing [&lt;ulink linkID="866408" linkType="Reference"&gt;866408&lt;/ulink&gt;]; however, by December 2007, development of the drug had been discontinued in favor of the improved analog &lt;ulink linkID="53039" linkType="Drug"&gt;&lt;/ulink&gt;&lt;ulink linkID="53039" linkType="Drug"&gt;CAT-8015&lt;/ulink&gt; (HA22)   [&lt;ulink linkID="865360" linkType="Reference"&gt;865360&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15856" linkType="Company"&gt;Genencor International&lt;/ulink&gt; was  previously developing CAT-3888, under license from the NCI; however, in November 2005, Genencor sold the immunotoxin to CAT [&lt;ulink linkID="631472" linkType="Reference"&gt;631472&lt;/ulink&gt;]. CAT-3888 was formerly being developed by &lt;ulink linkID="16045" linkType="Company"&gt;Enzon Pharmaceuticals Inc&lt;/ulink&gt;, under license from the NCI [&lt;ulink linkID="575452" linkType="Reference"&gt;575452&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2008, the product was granted EU Orphan Drug status for hairy cell leukemia [&lt;ulink linkID="970894" linkType="Reference"&gt;970894&lt;/ulink&gt;], [&lt;ulink linkID="972793" linkType="Reference"&gt;972793&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;BL-22&lt;/subtitle&gt;In February 2009, the NCI began a non-randomized, open-label, phase II study of BL-22 (&lt;ulink linkID="58084" linkType="Protocol"&gt;NCT00850525&lt;/ulink&gt;; CDR0000634993; NCI-09-C-0076; NCI-P07186) in patients (expected n = 25) with HCL who had relapsed or not responded to treatment. Patients would receive iv BL-22 for 30 min on days 1, 3 and 5 of a 4 week cycle. The primary endpoint would be response to treatment. Secondary endpoints would include safety and immunogenicity. The trial was estimated 	to complete in April 2012; in April 2012, the study was terminated as the supply of BL-22  expired and the sponsor was not interested in producing new supply [&lt;ulink linkID="987588" linkType="Reference"&gt;987588&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in February 2009, a non-randomized, open-label, phase II trial (&lt;ulink linkID="58084" linkType="Protocol"&gt;NCT00924040&lt;/ulink&gt;; 090076; 09-C-0076) began in an expected 25 patients with HCL who had previously received BL-22, &lt;ulink linkID="53039" linkType="Drug"&gt;CAT-8015&lt;/ulink&gt;, or &lt;ulink linkID="17767" linkType="Drug"&gt;LMB-2&lt;/ulink&gt;, or were ineligible for CAT-8015, but may benefit from BL22. The primary outcome would be response to treatment, and the trial was estimated to complete in April 2012;  in April 2012, the study was terminated as the supply of BL-22  expired and the sponsor was not interested in producing new supply  [&lt;ulink linkID="1024708" linkType="Reference"&gt;1024708&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, clinical data were presented at the 51st ASH meeting in New Orleans, LA. In a phase II trial, a total of 47% of patients achieved CR and the ORR was 72%. The median disease-free survival  and hematological remission  (HR) had not yet been  reached as the trial was ongoing. A total of 11/17 (65%) patients were in CR at median 46 (25 to 65) months and 12/22 (55%) patients were in HR at median 48 (25 to 65) months [&lt;ulink linkID="1059501" linkType="Reference"&gt;1059501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, clinical data were presented at the 51st ASH meeting in New Orleans, LA. In a phase I trial for HCL, 19 patients (61%)  showed complete remission (CR) most of which were after cycle 1, while 6 (19%) achieved a partial response. The overall response rate  (ORR) was 81%. The MTD was determined to be 40 microg/kg dosed three times. In a phase II trial, a total of 47% of patients achieved CR and the ORR was 72%. The median disease-free survival  and hematological remission  (HR) had not yet been  reached as the trial was ongoing. A total of 11/17 (65%) patients were in CR at median 46 (25 to 65) months and 12/22 (55%) patients were in HR at median 48 (25 to 65) months [&lt;ulink linkID="1059501" linkType="Reference"&gt;1059501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CAT-3888 studies&lt;/subtitle&gt;By October 2003, phase II  studies were underway in HCL [&lt;ulink linkID="575452" linkType="Reference"&gt;575452&lt;/ulink&gt;], [&lt;ulink linkID="667742" linkType="Reference"&gt;667742&lt;/ulink&gt;]; phase II trials in HCL were ongoing in February 2005 [&lt;ulink linkID="584377" linkType="Reference"&gt;584377&lt;/ulink&gt;]. In November 2005, clinical data on CAT-3888 in phase II studies in HCL patients were presented at the 17th AACR-NCI-EORTC conference in Philadelphia, PA.  Of 19 patients in phase II studies, 9 were followed up for at least 6 months and 6 of these achieved a complete remission, while 1 relapsed [&lt;ulink linkID="635841" linkType="Reference"&gt;635841&lt;/ulink&gt;]. In April 2006, further  data were presented on CAT-3888 at the 97th AACR meeting in Washington DC. By that time, a total of 25 patients with chemotherapy-resistant HCL were treated with CAT-3888; 11 had a complete response and 8 had a partial response. At that time, the study was ongoing with six patients still under retreatment [&lt;ulink linkID="657555" linkType="Reference"&gt;657555&lt;/ulink&gt;]. In June 2007, further clinical data were presented at the 43rd ASCO meeting in Chicago, IL. It was reported that CAT-3888 produced a high overall response rate, with the only reported serious adverse event being hemolytic uremic syndrome (reversible, grade 3) in one patient [&lt;ulink linkID="796388" linkType="Reference"&gt;796388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007,  data from a phase I trial in pediatric ALL patients were presented at the 43rd ASCO meeting in Chicago, IL. In the study, 18 patients were treated with 3 to 6 doses of 10 to 40 microg/kg of CAT-3888 in 21- to 28-day cycles. The drug was found to be well tolerated and no dose limiting toxicities were observed. In 16 subjects, decreased peripheral blast count, decreased marrow infiltration and decreased extramedullary disease was seen. A dose response was seen in 4 patients achieving stable disease at 30 microg/kg [&lt;ulink linkID="797439" linkType="Reference"&gt;797439&lt;/ulink&gt;].  In December 2007, further data from this study were presented at the 49th ASH meeting in Atlanta, GA. Of 23 patients, 18 achieved  a response. Responses corresponded with dose [&lt;ulink linkID="858253" linkType="Reference"&gt;858253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, phase I trials were ongoing for clinical subsets of pediatric acute lymphoblastic leukemia (pALL), chronic lymphocytic leukemia (CLL) and non-Hodgkins lymphoma (NHL) [&lt;ulink linkID="575452" linkType="Reference"&gt;575452&lt;/ulink&gt;]; by November 2005, results from all three trials were expected in 2006 [&lt;ulink linkID="637323" linkType="Reference"&gt;637323&lt;/ulink&gt;]. In November 2005, CAT intended to support the NCI's development of CAT-3888 in HCL and pALL, and the CLL indication was listed on the company's product pipeline [&lt;ulink linkID="667733" linkType="Reference"&gt;667733&lt;/ulink&gt;], [&lt;ulink linkID="631472" linkType="Reference"&gt;631472&lt;/ulink&gt;]; at that time, it was not known if the development of NHL was being continued by CAT, but the continuation of the studies was confirmed in March 2006 [&lt;ulink linkID="667742" linkType="Reference"&gt;667742&lt;/ulink&gt;]. By February 2005, phase II trials were ongoing for hairy cell leukemia (HCL), [&lt;ulink linkID="584377" linkType="Reference"&gt;584377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2004, a phase I trial was initiated by the NCI in patients with CD-22 positive leukemias and lymphomas in up to 54 patients.  In September 2005, a phase I study of 20 patients with CLL and NHL commenced.  These studies were to continue following CAT's licensing of the drug.  Data from the trials were to be released by the end of 2006 [&lt;ulink linkID="667742" linkType="Reference"&gt;667742&lt;/ulink&gt;]. In December 2007, data from 11 CLL and 4 NHL patients showed that no patients progressed while on treatment, and 1 CLL patient had a partial response to the drug [&lt;ulink linkID="860672" linkType="Reference"&gt;860672&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, phase I data on CAT-3888 were presented at the 39th ASCO meeting in Chicago, IL. Patients with HCL (n =31), CLL (n = 11) or non-Hodgkin's lymphoma (NHL) (n = 4) received doses of  CAT-3888 ranging from 6 to 50 microg/kg (every other day x 3) usually at three week to four week intervals for a median of three cycles. Due to hemolytic uremic syndrome observed in five patients (4 HCL, 1 NHL) receiving 30 microg/kg or more, the last six patients with HCL received 30 microg/kg during cycle one and 20 microg/kg during cycles two to five every six weeks. Complete response was observed in 33, 43, 82 and 100% of patients receiving &amp;lt; 20 (n = 3), 30 (n = 14), 40 (n = 11) and 50 (n = 3) microg/kg doses. A phase II trial of CAT-3888 was planned at a dose of 40 microg/kg/day for cycle one reduced to 30 microg/kg/day for subsequent cycles delivered every other day (x 3) every 4 weeks in  HCL patients [&lt;ulink linkID="492171" linkType="reference"&gt;492171&lt;/ulink&gt;]. Further data from the trial were presented in July 2003 at the 94th AACR meeting in Washington, DC. Of those patients with cladrabine-resistant HCL (n=31), complete remission was observed in 61% of patients and partial response in 19%. Four patients who relapsed from complete remission were retreated, three re-achieved complete remission, and at that time, one was still ongoing treatment. Out of 31 patients, 10 made high levels of neutralizing antibodies to CAT-3888 after 1-5 cycles of treatment [&lt;ulink linkID="497625" linkType="reference"&gt;497625&lt;/ulink&gt;]. In June 2004, long term follow-up data were presented at the 40th ASCO meeting in New Orleans, LA. Complete remission was observed in 19 patients at rates of 43%, 69% and 100% for patients receiving 30, 40 and 50 microg/kg, respectively. Eight patients had remained in complete remission for between 14 and 47 months. Hematologic remission was achieved in 21 of 29 patients. Five patients had developed hemolytic uremic syndrome (HUS), but this resolved in all patients without dialysis after 6 to 10 days of plasmapheresis. At that time, phase II testing was underway in HCL patients where three of three patients had achieved reversal of cytopenias [&lt;ulink linkID="541153" linkType="reference"&gt;541153&lt;/ulink&gt;]. In November 2005, clinical data on CAT-3888 in phase I  studies in HCL patients were presented at the 17th AACR-NCI-EORTC conference in Philadelphia, PA. Of 31 patients, 19 achieved complete remission and 6 had partial responses [&lt;ulink linkID="635841" linkType="Reference"&gt;635841&lt;/ulink&gt;]. Similar data were presented in April 2006 at the 97th AACR meeting in Washington DC  [&lt;ulink linkID="657555" linkType="Reference"&gt;657555&lt;/ulink&gt;], [&lt;ulink linkID="660926" linkType="Reference"&gt;660926&lt;/ulink&gt;], [&lt;ulink linkID="667742" linkType="Reference"&gt;667742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, clinical data on CAT-3888 were presented at the 9th Cancer Therapy with Antibodies and Immunoconjugates conference in Princeton, NJ. Of 12 patients, 11 showed complete response with median response times assessable to date, at one year. Toxicity was a decrease of albumin with the only immunogenicity occurring at the exotoxin segment; apoptosis of the treated cells was also observed. RNases conjugated to the anti-CD22 LL2 antibody to induce apoptosis in Daudi Burkitt's lymphoma cells demonstrated an enhanced in vitro potency by four orders of magnitude [&lt;ulink linkID="470743" linkType="reference"&gt;470743&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001,  data on CAT-3888 were presented at the 43rd ASH meeting in Orlando, FL. In the trial, 25 patients with HCL resistant to &lt;ulink linkID="3490" linkType="Drug"&gt;cladribine&lt;/ulink&gt; received 128 cycles of CAT-3888 at 3 to 50 microg/kg every other day for three doses. Complete remissions (CRs) were experienced by 18 patients (72%), and three partial responses (12%) were observed [&lt;ulink linkID="432937" linkType="reference"&gt;432937&lt;/ulink&gt;], [&lt;ulink linkID="475211" linkType="reference"&gt;475211&lt;/ulink&gt;]. These results were also presented at the 38th ASCO meeting in Orlando, FL. At 1 to 28 months follow-up, four of the patients who had shown CR had since relapsed without cytopenias, but three of three re-achieved complete remission with further CAT-3888 treatment. CAT-3888 was most efficacious when tumor mass was low, but efficacy was unrelated to &lt;ulink linkID="3490" linkType="Drug"&gt;cladribine&lt;/ulink&gt; resistance. The DLT was reversible hemolytic uremic syndrome observed at 30 to 50 microg/kg [&lt;ulink linkID="453814" linkType="reference"&gt;453814&lt;/ulink&gt;], [&lt;ulink linkID="475211" linkType="reference"&gt;475211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, results from a phase I trial investigating the effect of CAT-3888 in patients with chemotherapy-resistant B-cell malignancies were presented at the 92nd AACR meeting in New Orleans, LA. Of 29 patients completing treatment, 14 had HCL and in these patients 11 CRs were observed. The CR rate was 100% (including 3 with variant HCL) in patients without pre-existing antibodies at dose levels of 10 to 50 microg/kg every other day for 3 doses (qid x 3). Of 11 patients in CR, 9 developed expansions of cytotoxic T cells (CTCs), assessed by flow cytometry as abnormally high levels of CD3+/CD16+, CD3+/CD56+, CD3+/CD57+ and/or CD3+/CD8+ lymphocytes [&lt;ulink linkID="405138" linkType="reference"&gt;405138&lt;/ulink&gt;], [&lt;ulink linkID="403312" linkType="reference"&gt;403312&lt;/ulink&gt;]. These data were also presented in May 2001 at the 37th ASCO meeting in San Francisco, CA [&lt;ulink linkID="410391" linkType="reference"&gt;410391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, data from a phase I trial in 31 patients were presented at the 42nd ASH meeting in San Francisco, CA. Patients with refractory or variant hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) received 99 cycles of CAT-3888 at 3 to 50 microg/kg iv every other day for three doses. The highest dose was considered dose limiting, and the MTD was 40 microg/kg, where all 18 cycles in ten patients were well tolerated. Of the 11 evaluable refractory HCL patients,  10 achieved complete response and 1 achieved partial response. Complete responses were also observed in all three variant HCL patients. Clinically useful effects were observed in the CLL patients, but no complete responses [&lt;ulink linkID="393827" linkType="reference"&gt;393827&lt;/ulink&gt;], [&lt;ulink linkID="403312" linkType="reference"&gt;403312&lt;/ulink&gt;]. In August 2002, similar results were presented at the First International Targeted Therapies Congress in Washington DC [&lt;ulink linkID="463418" linkType="reference"&gt;463418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, findings from a phase I trial in seven patients with HCL were presented at the 91st AACR meeting in San Francisco, CA. There were two complete responses (after 2 and 4 months) and three partial responses following treatment with CAT-3888 at doses of over 6 microg/kg. The maximum tolerated dose was not reached in this study [&lt;ulink linkID="362451" linkType="reference"&gt;362451&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, positive results of a clinical trial comparing &lt;ulink linkID="17767" linkType="Drug"&gt;LMB-2&lt;/ulink&gt;  and CAT-3888 were presented at the 36th ASCO meeting in New Orleans, LA. Both treatments produced durable responses in chemotherapy-refractory HCL, while sparing resting T cells [&lt;ulink linkID="368839" linkType="reference"&gt;368839&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;By 1995, phase I trials of &lt;ulink linkID="41157" linkType="Drug"&gt;IgG-RFB4-SMPT-dgA&lt;/ulink&gt; had commenced for the treatment of B-cell lymphoma [&lt;ulink linkID="185811" linkType="reference"&gt;185811&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2007, preclinical data were presented at the 43rd ASCO meeting in Chicago. In vitro, CAT-3888 induced cytotoxicity against blast samples from 42 children with CD22+ ALL, and a dose response was seen in murine xenografts along with a significantly increased survival time [&lt;ulink linkID="797439" linkType="Reference"&gt;797439&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2005, data were published on increasing the activity of CAT-3888 through in vitro antibody evolution targeting germline hotspots. The germline hot spot (Ser(30)-Asn(31)) within CDR1 of the antibody light chain was mutated. Substitutions with arginine at either position produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold over CAT-3888 (5.8 nM) and 3-fold over the first generation mutant CAT-8015 (2.3 nM). More importantly, a 10-fold increase in activity over CAT-3888 and a 2-3-fold increase over CAT-8015 were observed in various B lymphoma cell lines [&lt;ulink linkID="595437" linkType="Reference"&gt;595437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, research was published on the cytotoxic activity of SS1(dsFv)PE38 against peritoneal mesothelioma tumor cell lines. The compound inhibited growth of several of the cell lines. The data suggested that high mesothelin expression correlated with sensitivity to the compound  [&lt;ulink linkID="595462" linkType="Reference"&gt;595462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, preclinical data on CAT-3888 were presented at the 46th ASH meeting in San Diego, CA. The cytotoxicity of CAT-3888 was measured in NCEB-1, Granta-519 and SU-DHL-4 cell lines. NCEB-1 cells were treated with 1 microg/ml CAT-3888 for 24 to 32 h, causing a reduction in the numbers of viable cells in comparison to cells exposed to a non-binding immunotoxin. Apoptosis induction was not was not detected before 48 h of exposure. Incorporation of bromo-deoxyuridine into DNA was almost completely inhibited after 24 h. The numbers of cells in the G1 phase were increased when treated with CAT-3888.  Levels of cyclins A, E, D1 and D3 were markedly reduced compared to cdk2 and cdk4 protein expression levels, which remained unchanged. Expression of the retinoblastoma protein was decreased, and the protein was hypophosphorylated in immunotoxin-treated cells. The compound inhibited synthesis of cyclins E and D1. Similar results were obtained in Granta-519 cells. SU-DHL-4 diffuse, large-cell lymphoma cells were highly sensitive to CAT-3888, and G1 arrest was observed as early as 8 to 24 h after exposure in these cells. Cyclin A, D3 and E expression was decreased, while cyclin D1 was not expressed in SU-DHL-4 cells. Cell cycle arrest did not prevent the subsequent induction of apoptosis in lymphoma cells that had been continuously exposed to the immunotoxin [&lt;ulink linkID="574360" linkType="Reference"&gt;574360&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2003, preclinical data on CAT-3888 were presented at the 45th ASH meeting in San Diego, CA. The activity of the compound was studied in B-cell CLL in vitro. The anitleukemic activity of CAT-3888 correlated with CD22 expression. The compound induced mitochondrial damage and caspase-dependent apoptosis, and had synergistic activity with vincristine and doxorubicin. Mutation of CAT-3888 to improve target binding gave CAT-8015, which showed increased activity against B-CLL  [&lt;ulink linkID="595541" linkType="Reference"&gt;595541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, preclinical data on CAT-3888 were presented at the 44th ASH meeting in Philadelphia, PA. The agent was effective against acute lymphocytic leukemia (ALL) cell lines as well as primary ALL cells. At a dose range of 100 to 300 microg/kg the survival of SCID mice engrafted with EU-1 ALL cells was increased in a dose-dependent manner [&lt;ulink linkID="474030" linkType="reference"&gt;474030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, data were published on the in vitro effect of CAT-3888 in overcoming resistance to apoptosis in CLL was studied using B cell from 22 patients with CLL. Good correlation was found between CD22 expression and apoptosis induction after CAT-3888 treatment. Interleukin-4 failed to prevent apoptosis. The combination of vincristine and CAT-3888 displayed a marked antileukemic effect and the antileukemic activity of fludarabine and doxorubicin was augmented by CAT-3888. Combination with chemotherapy was expected to improve the efficacy of immunotoxin treatment in patients [&lt;ulink linkID="595340" linkType="Reference"&gt;595340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1999, preclinical data were presented at the 90th AACR meeting in Philadelphia, PA. CAT-3888 was toxic for CD22+ cells and exhibited antitumor activity in nude mice bearing human B-cell lymphomas. Administration of the drug (0, 0.1, 1.0, 1.25, 1.75 and 2.0 mg/kg iv qid every other day) produced lethargy and non dose-related leukocytosis in all dose groups. No significant changes were noted in the percentage of mononuclear cell populations positive for CD20 or CD22. Elevated heart rate and mean arterial pressure occurred at 2.0 mg/kg. Plasma levels ranged from 2.5 to 53 microg/ml (0.1 to 2.0 mg/kg) 10 min post dose [&lt;ulink linkID="321266" linkType="reference"&gt;321266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1998, data were presented showing that   CAT-3888 was selectively cytotoxic towards fresh malignant cells from patients with B-cell leukemias and very high blood levels were obtained in monkeys [&lt;ulink linkID="289046" linkType="reference"&gt;289046&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2005,  &lt;ulink linkID="24236" linkType="Company"&gt;&lt;/ulink&gt;CAT acquired two anticancer immunotoxins, CAT-3888 and &lt;ulink linkID="53039" linkType="Drug"&gt;&lt;/ulink&gt;&lt;ulink linkID="53039" linkType="Drug"&gt;CAT-8015&lt;/ulink&gt;,  from Genencor for up to $16 million. At that time, CAT hired ten key former employees of Genencor who would continue to be responsible for the development of the programs in Palo Alto, CA. Under the terms of the agreement, Genencor received $14 million upfront, which it  used to purchase 2.27% of CAT's issued share capital. CAT may have been required to pay an additional $2 million, depending on the availability of Genencor-produced CAT-3888 bulk material for use in a clinical trial. CAT would assume Genencor's CRADA with the NCI [&lt;ulink linkID="631472" linkType="Reference"&gt;631472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, Genencor  signed an exclusive worldwide patent license agreement giving it the right to develop and commercialize CAT-3888 and CAT-8015 from the NCI. A CRADA would be signed in conjunction with the license agreement, under which Genencor would assume responsibility for the development and commercialization of CAT-3888. Genencor would also initiate the development of CAT-8015 in a broader range of CD22-expressing hematologic malignancies [&lt;ulink linkID="575452" linkType="Reference"&gt;575452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, Enzon agreed to codevelop CAT-3888 with the NIH under a CRADA, which was in the final stages of approval at the NIH. Enzon also applied for an exclusive license for worldwide commercialization rights and access to a patent estate consisting of several dozen US and international patents and patent applications, claiming, among other things, the composition and production of the SS1P molecule, as well as its therapeutic application in cancers expressing mesothelin. The proposed license would be exclusive in the fields of cancers expressing mesothelin. The CRADA was to be for an initial period of 3 years, with an option to extend. It also included a research project to further optimize CAT-3888 using Enzon's proprietary macromolecular engineering technologies [&lt;ulink linkID="514019" linkType="reference"&gt;514019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;For an expert analysis of the development of this therapy as of January 2002, please see the Drug Evaluation.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-07T00:00:00.000Z</StatusDate><Source id="865360" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-07T00:00:00.000Z</StatusDate><Source id="865360" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-07T00:00:00.000Z</StatusDate><Source id="865360" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16045">Enzon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16045">Enzon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-07T00:00:00.000Z</StatusDate><Source id="865360" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="987588" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="987588" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-31T00:00:00.000Z</StatusDate><Source id="430257" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16045">Enzon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-19T00:00:00.000Z</StatusDate><Source id="514019" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16045">Enzon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-19T00:00:00.000Z</StatusDate><Source id="514019" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-07-20T00:00:00.000Z</StatusDate><Source id="474030" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-19T00:00:00.000Z</StatusDate><Source id="514019" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-09-06T00:00:00.000Z</StatusDate><Source id="185811" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-19T00:00:00.000Z</StatusDate><Source id="514019" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-31T00:00:00.000Z</StatusDate><Source id="667742" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15856">Genencor International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="575452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24236">Cambridge Antibody Technology Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24236">Cambridge Antibody Technology Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="631472" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24236">Cambridge Antibody Technology Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="667742" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24236">Cambridge Antibody Technology Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-01T00:00:00.000Z</StatusDate><Source id="667742" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-29T00:00:00.000Z</StatusDate><Source id="845057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-29T00:00:00.000Z</StatusDate><Source id="845057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-29T00:00:00.000Z</StatusDate><Source id="845057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-29T00:00:00.000Z</StatusDate><Source id="845057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="987588" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1736">Hairy cell leukemia</Indication><AwardedIndication>Treatment of hairy cell leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-05T00:00:00.000Z</MileStoneDate><Source id="972793" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="1736">Hairy cell leukemia</Indication><AwardedIndication>Treatment of hairy cell leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-08T00:00:00.000Z</MileStoneDate><Source id="972793" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00381"><Name>B-lymphocyte cell adhesion molecule</Name><SwissprotNumbers><Swissprot>P20273</Swissprot><Swissprot>P35329</Swissprot><Swissprot>Q9N1E3</Swissprot><Swissprot>Q9N1E4</Swissprot><Swissprot>Q9N1E5</Swissprot><Swissprot>Q9N1E6</Swissprot></SwissprotNumbers></Target><Target id="PTGT-09718"><Name>Elongation factor 2</Name><SwissprotNumbers><Swissprot>A0B7D5</Swissprot><Swissprot>A0SXL6</Swissprot><Swissprot>A1RVX2</Swissprot><Swissprot>A3CXM8</Swissprot><Swissprot>A3DMV6</Swissprot><Swissprot>A3MSN3</Swissprot><Swissprot>A4FWF0</Swissprot><Swissprot>A4WMR8</Swissprot><Swissprot>A4YCV9</Swissprot><Swissprot>A5DI11</Swissprot><Swissprot>A5ULM6</Swissprot><Swissprot>A6UV44</Swissprot><Swissprot>A6VGV5</Swissprot><Swissprot>A7I4X4</Swissprot><Swissprot>A8ACA7</Swissprot><Swissprot>O14460</Swissprot><Swissprot>O23755</Swissprot><Swissprot>O27131</Swissprot><Swissprot>O28385</Swissprot><Swissprot>O59521</Swissprot><Swissprot>O93632</Swissprot><Swissprot>O93637</Swissprot><Swissprot>O93640</Swissprot><Swissprot>P05197</Swissprot><Swissprot>P09445</Swissprot><Swissprot>P09445</Swissprot><Swissprot>P09604</Swissprot><Swissprot>P13060</Swissprot><Swissprot>P13639</Swissprot><Swissprot>P15112</Swissprot><Swissprot>P23112</Swissprot><Swissprot>P26752</Swissprot><Swissprot>P28996</Swissprot><Swissprot>P29691</Swissprot><Swissprot>P30925</Swissprot><Swissprot>P32324</Swissprot><Swissprot>P33159</Swissprot><Swissprot>P55823</Swissprot><Swissprot>P58252</Swissprot><Swissprot>P61877</Swissprot><Swissprot>P61878</Swissprot><Swissprot>Q06193</Swissprot><Swissprot>Q17152</Swissprot><Swissprot>Q1HPK6</Swissprot><Swissprot>Q23716</Swissprot><Swissprot>Q2NEL0</Swissprot><Swissprot>Q3IUM4</Swissprot><Swissprot>Q3SYU2</Swissprot><Swissprot>Q464Z3</Swissprot><Swissprot>Q58448</Swissprot><Swissprot>Q5JFZ3</Swissprot><Swissprot>Q5R8Z3</Swissprot><Swissprot>Q5UZS7</Swissprot><Swissprot>Q6BJ25</Swissprot><Swissprot>Q6CPQ9</Swissprot><Swissprot>Q6FYA7</Swissprot><Swissprot>Q6L200</Swissprot><Swissprot>Q6LXI2</Swissprot><Swissprot>Q74M52</Swissprot><Swissprot>Q754C8</Swissprot><Swissprot>Q874B9</Swissprot><Swissprot>Q875S0</Swissprot><Swissprot>Q875Z2</Swissprot><Swissprot>Q8PUR7</Swissprot><Swissprot>Q8TRC3</Swissprot><Swissprot>Q8TXJ4</Swissprot><Swissprot>Q8ZZC1</Swissprot><Swissprot>Q90705</Swissprot><Swissprot>Q96X45</Swissprot><Swissprot>Q975H5</Swissprot><Swissprot>Q979T3</Swissprot><Swissprot>Q9HM85</Swissprot><Swissprot>Q9V1Z8</Swissprot><Swissprot>Q9YC19</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1011177">Genecor International Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1155603">DowDuPont Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16045">Enzon Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="15">Drug - CRADA</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="107523" title="Genencor International to acquire rights to the National Cancer Institute's CAT-3888 and CAT-8015 worldwide for cancer"></Deal><Deal id="108367" title="CAT to acquire Genencor's anticancer immunotoxins "></Deal><Deal id="113469" title="Enzon and NIH to codevelop CAT-3888  "></Deal></Deals><PatentFamilies><PatentFamily id="1658691" number="WO-2011031441" title="Therapy with a chimeric molecule and a pro-apoptotic agent"></PatentFamily><PatentFamily id="1885631" number="WO-2008109005" title="Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of B cell cancers"></PatentFamily><PatentFamily id="1958992" number="WO-2007112047" title="Formulations containing immunotoxins targeted to the mesothelin tumor cell antigen"></PatentFamily><PatentFamily id="243994" number="WO-09725068" title="Mesothelium antigen and methods and kits for targeting it."></PatentFamily><PatentFamily id="372026" number="WO-2012054679" title="Methods for processing inclusion bodies"></PatentFamily><PatentFamily id="940328" number="WO-03027135" title="Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DowDuPont Inc" id="1155603"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enzon Pharmaceuticals Inc" id="16045"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>